In an early phase multicenter study, reductions in lipoprotein(a) to undetectable levels were achieved with a small interfering RNA therapeutic, lepodisiran.
Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.
Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.
Successful early studies reported for two Lp(a)-lowering therapies healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Study investigators offered updated data from 2 key trials presented in the past year: CLEAR Outcomes in low-density lipoprotein cholesterol and OCEAN(a)-DOSE in lipoprotein (a).